Drugs / 18F-92
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04926272 | Jul 2021 → Jul 2024 | Alzheimer disease | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-92 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04926272 ↗ |
| Modality | Diagnostic / imaging agent | “18F-92 molecular probe is a novel molecularly targeted imaging agent” NCT04926272 ↗ |
| Route | Intravenous | “Intravenous injection of one dose of 0.10mCi/kg(±5%) 18F-92.” NCT04926272 ↗ |